Haleon plc, a major player in the biotechnology market, has been actively pursuing a strategic
share buyback program throughout this period. Significant stakes once held by
GSK and
Pfizer in the company have been sold off, with GSK divesting its entire share and Pfizer reducing its stake from 32% to 24%. Notably, share buybacks and divestments by key investors are driving substantial market activity for Haleon. This includes a £1.25 billion final Haleon share sale by GSK, and Pfizer collecting approximately $2.6 billion from its Haleon sell-off. Despite risks posed by Haleon stocks in August, the company's value has been boosted by top-line growth, and it managed to impress with an 11% profit increase in its first-half results. Additionally,
Morgan Stanley increased its price target for Haleon, but removed the firm from its Top Pick. However,
Goldman Sachs switched its rating to 'Neutral' citing overvaluation. Haleon also seeks to make a mark abroad, specifically in the Chinese market where it has increased its JV stake to 88% for £500 million.
Haleon Stocks News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Fri, 27 Sep 2024 12:32:37 GMT -
Rating 7
- Innovation 3
- Information 9
- Rumor -3
